Applying for research grants
The MS Society is the largest dedicated charitable funder of MS research in the UK, and is committed to supporting the highest quality research relating to the cause and treatment of MS.
Through our application and review process we aim to fund the highest quality MS research, and to support the highest calibre researchers, in order to derive maximum benefit for people with MS.
New Research Strategy
The MS Society has now launched a new Research Strategy which must be considered when making research grant applications. Read our new Research Strategy.
Grant Round 1
Grant Round 1 for Project Grants, PhD Studentships and Innovative awards (all areas of research) and Junior Fellowship awards (care and services research only) is now closed. Funding decisions will be communicated to applicants at the end of the summer.
Further funding opportunities: Secondary Progressive MS Clinical Trial Call
We are in receipt of additional restricted funds. In line with our new research strategy, and in addition to our regular grant round, we are running a specific call for applications which focus on clinical trials for secondary progressive MS.
Applications to this round must:
- be a clinical trial of a medicinal product which is already licensed in the UK and in use for another condition (repurposing)
- be aimed at reducing the accumulation of disability in people with secondary progressive MS
- include people with secondary progressive MS as trial participants
Applications to this round must request no more than £500,000 from the Society.
This call is now closed, funding decisions will be communicated at the end of the summer. As funding for this round will be restricted, applications to this round which are not successful but meet the eligibility criteria will be considered as part of Grant Round 1.
MRCT - MS Society joint call for targets
MRC Technology and the MS Society are working together to develop novel therapeutics for the treatment of MS.
This call aims to fund one or two projects focussed on potential small molecule or antibody targets to slow, stop or reverse progression in MS or treat MS symptoms, to a maximum value of £150,000. Upon completion, projects will be evaluated by MRC Technology for further development as small molecule or therapeutic antibody projects.
The deadline for outline applications has closed. Decisions will be communicated to the applicants by the beginning of summer.